# Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

> **NCT00419341** · PHASE3 · COMPLETED · sponsor: **CSL Behring** · enrollment: 49 (actual)

## Conditions studied

- Primary Immune Deficiency

## Interventions

- **BIOLOGICAL:** Human Normal Immunoglobulin for Subcutaneous Administration

## Key facts

- **NCT ID:** NCT00419341
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2013-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00419341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00419341, "Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00419341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*